29 januari 2018: Bron: Chinese Journal of Integrative Medicine

Dat TCM - Traditionele Chinese Medicijnen / kruiden een meerwaarde kunnen betekenen in het behandelen van kanker is al vele malen bewezen. Hier weer een studie, nu bij longkankerpatiënten(stadium III/IVa niet-kleincellige longkanker), die nog geen chemo hadden gehad) met een EGFR mutatie waarvoor Gefitinib - Iressa of Erlotinib - Tarceva de standaard berhandeling is mocht immuuntherapie met een anti-PD medicijn om bepaalde redenen niet beschkbaar zijn als behandelingsoptie.

(zie ook de literatuurlijsten van niet-toxische stoffen en behandelingen waarin TCM - Traditionele Chinese Medicijnen / Kruiden vaak worden genoemd bij nagenoeg alle vormen van kanker c.q. chemo en radiotherapie). De natuurapotheek heeft de meeste Chinese kruiden wel en soms kunnen ze ze ook bestellen of zelf maken als ze die niet in voorraad hebben.

Foto: Fuzheng Kang’ai Formula

In een gerandomiseerde studie bij totaal 70 patiënten met longkanker met positieve epidermal growth factor receptor (EGFR) mutatie blijken de 35 patiënten uit de groep die naast Gefitinib - Iressa ook dagelijks een mengsel van Chinese kruiden onder de naam Fuzheng Kang’ai Formula (250 ml 2x per dag) oraal innamen het veel beter deden op ziektevrije tijd, mediane overall overleving en van die patiënten beriekten ook meer mensen een complete remissie.

Uit het abstract:

Alle patiënten hebben de studie tot het eind aan toe gevolgd. De 35 patiënten uit de GF groep (Gefitinib / Iressa plus Fuzheng Kang’ai Formula) hadden een statistisch significant langere ziektevrije tijd (PFS) en Mediane stabiele ziekte (MST) vergeleken met de G groep (alleen gefitinib - Iressa), met een mediane PFS van 12.5 maanden (95% CI 3.30–21.69) vs. 8.4 maanden (95% CI 6.30–10.50; log-rank P<0.01),

Een MST van 21.5 maanden (95% CI 17.28–25.73) vs. 18.3 maanden (95% CI 17.97–18.63; log-rank P<0.01). Mediane overall overleving (ORR) en ziektevrije overall overleving (DCR) in de GF group en G group waren respectievelijk 65.7% vs. 57.1% en 94.3% vs. 80.0% (P>0.05).

De meest voorkomende bijwerkingen in de GF groep en G groep waren jeuk of acne (42.8% vs. 57.1%, P>0.05), diarree (11.5% vs. 31.4%, P<0.05), en stomatitis (2.9% vs. 8.7%, P>0.05).

De onderzoekers concluderen dan ook:

Patiënten met gevorderde niet-kleincellige longkanker geselecteerd op basis van een EGFR mutatie berieken een langere ziektevrije tijd en mediane overall overleving met minder bijwerkingen als zij een behandeling krijgen met de combinatie van gefitinib / Iressa plus Fuzheng Kang’ai Formula (FZKA) in vergelijking met alleen gefitinib / Iressa.

Het volledige studierapport: Gefitinib plus Fuzheng Kang’ai Formula (扶正抗癌方) in patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutation: A randomized controlled trial is tegen betaling in te zien.

Hier het originele abstract waaruit ik bovenstaand in het Nederlands heb vertaald. Plkus referentielijst

Patients with advanced non-small cell lung cancer selected by EGFR mutations have longer PFS, MST and with less toxicity if they are treated with gefifitinib plus FZKA than gefifitinib alone.

Chinese Journal of Integrative Medicine

pp 1–7 | Cite as

Gefitinib plus Fuzheng Kang’ai Formula (扶正抗癌方) in patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutation: A randomized controlled trial

Xiao-bing Yang
Xiao-shu Chai
Wan-yin WuEmail author
Shun-qin Long
Hong Deng
Zong-qi Pan
Wen-feng He
Yu-shu Zhou
Gui-ya Liao
Shu-jing Xiao

Xiao-bing Yang
- 1
Xiao-shu Chai
- 1
Wan-yin Wu
- 1
Email author
Shun-qin Long
- 1
Hong Deng
- 1
Zong-qi Pan
- 1
Wen-feng He
- 1
Yu-shu Zhou
- 1
Gui-ya Liao
- 1
Shu-jing Xiao
- 1

1.Department of OncologyGuangdong Provincial Hospital of Traditional Chinese MedicineGuangzhouChina

Original Article

First Online: 09 August 2017

44 Downloads

Abstract

Objective

To evaluate the effect of Fuzheng Kang’ai Formula (扶正抗癌方, FZKA) plus gefitinib in patients with advanced non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations.

Methods

A randomized controlled trial was conducted from 2009 to 2012 in South China. Seventy chemotherapynaive patients diagnosed with stage IIIB/IV non-small cell lung cancer with EGFR mutations were randomly assigned to GF group [gefifitinib (250 mg/day orally) plus FZKA (250 mL, twice per day, orally); 35 cases] or G group (gefifitinib 250 mg/day orally; 35 cases) according to the random number table and received treatment until progression of the disease, or development of unacceptable toxicities. The primary endpoint [progression-free survival (PFS)] and secondary endpoints [median survival time (MST), objective response rate (ORR), disease control rate (DCR) and safety] were observed.

Results

No patient was excluded after randomization. GF group had signifificantly longer PFS and MST compared with the G group, with median PFS of 12.5 months (95% CI 3.30–21.69) vs. 8.4 months (95% CI 6.30–10.50; log-rank P<0.01), MST of 21.5 months (95% CI 17.28–25.73) vs. 18.3 months (95% CI 17.97–18.63; log-rank P<0.01). ORR and DCR in GF group and G group were 65.7% vs. 57.1%, 94.3% vs. 80.0%, respectively (P>0.05). The most common toxic effect in the GF group and G group were rash or acne (42.8% vs. 57.1%, P>0.05), diarrhea (11.5% vs. 31.4%, P<0.05), and stomatitis (2.9% vs. 8.7%, P>0.05).

Conclusion

Patients with advanced non-small cell lung cancer selected by EGFR mutations have longer PFS, MST and with less toxicity if they are treated with gefifitinib plus FZKA than gefifitinib alone.

Keywords

non-small cell lung cancer gefifitinib Chinese medicine combination therapy sensitizing effect Fuzheng Kang’ai Formula randomized controlled trial

Supported by the National Natural Science Foundation of China (No. 81273965, 81503507) and the Natural Science Foundation of Guangdong Province (No. 2015A030310245)

References

1.

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin 2010;60:277–300.CrossRefPubMedGoogle Scholar
2.

Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92–98.CrossRefPubMedGoogle Scholar
3.

Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367–1380.CrossRefPubMedGoogle Scholar
4.

Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 Trial). J Clin Oncol 2003;21:2237–2246.CrossRefPubMedGoogle Scholar
5.

Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149–2158.CrossRefPubMedGoogle Scholar
6.

Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST): a randomized phase III trial. Lancet 2008;372:1809–1818.CrossRefPubMedGoogle Scholar
7.

Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008;26:4244–4252.CrossRefPubMedGoogle Scholar
8.

Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multi-centre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527–1537.CrossRefGoogle Scholar
9.

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–957.CrossRefPubMedGoogle Scholar
10.

Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958–967.CrossRefPubMedGoogle Scholar
11.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129–2139.CrossRefPubMedGoogle Scholar
12.

Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497–1500.CrossRefPubMedGoogle Scholar
13.

Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919–8923.CrossRefPubMedGoogle Scholar
14.

Tamura K, Okamoto I, Kashii T, Negoro S, Hirashima T, Kudoh S, et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 2008;98:907–914.CrossRefPubMedPubMedCentralGoogle Scholar
15.

Morita S, Okamoto I, Kobayashi K, Yamazaki K, Asahina H, Inoue A, et al. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2009;5:4493–4498.CrossRefGoogle Scholar
16.

Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009;15:5267–5273.CrossRefPubMedPubMedCentralGoogle Scholar
17.

Hyodo I, Amano N, Eguchi K, Narabayashi M, Imanishi J, Hirai M, et al. Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol 2005;23:2645–2654.CrossRefPubMedGoogle Scholar
18.

Swarup AB, Barrett W, Jazieh AR. The use of complementary and alternative medicine by cancer patients undergoing radiation therapy. Am J Clin Oncol 2006;29:468–473.CrossRefPubMedGoogle Scholar
19.

Ezeome ER, Anarado AN. Use of complementary and alternative medicine by cancer patients at the University of Nigeria Teaching Hospital, Enugu, Nigeria. BMC Complement Altern Med 2007;7:28.CrossRefPubMedPubMedCentralGoogle Scholar
20.

Chan KK, Yao TJ, Jones B, Zhao JF, Ma FK, Leung CY, et al. The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring. Ann Oncol 2011;22:2241–2249.CrossRefPubMedGoogle Scholar
21.

Liu ML, Chien LY, Tai CJ, Lin KC. Effectiveness of traditional Chinese medicine for liver protection and chemotherapy completion among cancer patients. Evid Based Complement Alternat Med 2011;2011:291843.PubMedPubMedCentralGoogle Scholar
22.

Yamamoto K, Hoshiai H, Noda K. Effects of Shakuyakukanzo-to on muscle pain from combination chemotherapy with paclitaxel and carboplatin. Gynecol Oncol 2001;81:333–334.CrossRefPubMedGoogle Scholar
23.

Mori K, Kondo T, Kamiyama Y, Kano Y, Tominaga K. Preventive effect of Kampo medicine (Hangeshashinto) against irinotecan-induced diarrhea in advanced nonsmall-cell lung cancer. Cancer Chemother Pharmacol 2003;51:403–406.PubMedGoogle Scholar
24.

Zheng F, Wu JJ, Li X, Tang Q, Yang LJ, Yang XB, et al. Chinese herbal medicine Fuzheng Kang-Ai Decoction inhibited lung cancer cell growth through AMPKα-mediated induction and interplay of IGFBP1 and FOXO3a. Evid Based Complement Alternat Med 2016;2016:5060757.PubMedPubMedCentralGoogle Scholar
25.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205–216.CrossRefGoogle Scholar
26.

Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, et al. Analysis of any point mutation in DNA: the amplification refractory mutation system (ARMS). Nucleic Acids Res 1989;17:2503–2516.CrossRefPubMedPubMedCentralGoogle Scholar
27.

Whitcombe D, Theaker J, Guy SP, Brown T, Little S. Detection of PCR products using self-probing amplicons and fl uorescence. Nat Biotechnol 1999;17:804–807.CrossRefPubMedGoogle Scholar
28.

Wu WY, Yang XB, Deng H, Long SQ, Sun LS, He WF, et al. Treatment of advanced non-small cell lung cancer with extracorporeal high frequency thermotherapy plus traditional Chinese medicine. Chin J Integr Med 2010;16:406–410.CrossRefPubMedGoogle Scholar
29.

Cancer Therapy Evaluation Program. Common terminology criteria for adverse events (CTCAE) v3.0. National Cancer Institute. Accessed July 10, 2013. Available at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.Google Scholar
30.

Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, et al. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330–353.CrossRefPubMedGoogle Scholar
31.

Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92–98.CrossRefPubMedGoogle Scholar
32.

Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121–128.CrossRefPubMedGoogle Scholar
33.

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380–2388.CrossRefPubMedGoogle Scholar
34.

Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786–792.CrossRefPubMedGoogle Scholar
35.

Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039–1043.CrossRefPubMedGoogle Scholar
36.

Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011;29:3307–3015.CrossRefPubMedGoogle Scholar
37.

Xu L, Li H, Xu Z, Wang Z, Liu L, Tian J, et al. Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients. BMC Complement Altern Med 2012;12:112.CrossRefPubMedPubMedCentralGoogle Scholar
38.

Ma JJ, Liu HP. Efficacy of Aidi Injection on overexpression of P-glycoprotein induced by vinorelbine and cisplatin regimen in patients with non-small cell lung cancer. Chin J Integr Med 2017;23:504–509.CrossRefPubMedGoogle Scholar
39.

Sima L. The assessment of randomized controlled clinical trial of Banxia Xiexin Prescription in treating erlotinib-induced skin rash in NSCLC patients. Ann Oncol 2009;20:43–46.CrossRefGoogle Scholar
40.

Hwang SW, Han HS, Lim KY, Han JY. Drug interaction between complementary herbal medicines and gefitinib. J Thorac Oncol 2008;3:942–943.CrossRefPubMedGoogle Scholar